Tokyo, Japan

Tatsuhiro Shibata

USPTO Granted Patents = 2 


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Tatsuhiro Shibata: Innovator in Cancer Therapeutics

Introduction

Tatsuhiro Shibata is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer therapeutics, particularly in the development of innovative treatment agents. With a total of 2 patents, his work focuses on addressing critical challenges in cancer treatment.

Latest Patents

Shibata's latest patents include a therapeutic agent for bile duct cancer. This invention comprises 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof. Additionally, he has developed a patent related to the oncogene NRF2. This invention provides a marker that can be used as an indicator for efficacy prediction of an mTOR-related anticancer agent or for prognostic prediction. It also includes a method for efficacy evaluation of a cancer drug by detecting NRF2 abnormality, along with a novel anticancer agent targeting NRF2.

Career Highlights

Throughout his career, Tatsuhiro Shibata has worked with esteemed organizations such as the National Cancer Center and Infocom Corporation. His experience in these institutions has allowed him to contribute significantly to cancer research and therapeutic development.

Collaborations

Shibata has collaborated with notable colleagues, including Shigeru Saito and Yasuhito Arai. These partnerships have further enhanced his research and innovation in the field of cancer therapeutics.

Conclusion

Tatsuhiro Shibata is a dedicated inventor whose work in cancer therapeutics has the potential to make a significant impact on treatment options for patients. His innovative patents and collaborations reflect his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…